New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
A potential therapeutic vaccine strategy for a subset of myeloproliferative neoplasms

A potential therapeutic vaccine strategy for a subset of myeloproliferative neoplasms

by Ludwig Cancer ResearchCredit: CC0 Public DomainThe cells of a subset of myeloproliferative neoplasms (MPNs), slow-growing blood cancers, have frameshift mutations in their calreticulin (CALR)
Oncology January 29,2024
A potential therapeutic vaccine strategy for a subset of myeloproliferative neoplasms

A potential therapeutic vaccine strategy for a subset of myeloproliferative neoplasms

by Ludwig Cancer ResearchCredit: CC0 Public DomainThe cells of a subset of myeloproliferative neoplasms (MPNs), slow-growing blood cancers, have frameshift mutations in their calreticulin (CALR)
Oncology January 29,2024
Night work may increase the risk of aggressive prostate cancer in offshore petroleum workers

Night work may increase the risk of aggressive prostate cancer in offshore petroleum workers

by University of Oslo, Faculty of MedicineExposure-risk curve for a non-linear model of rollover shift work exposure, generated using restricted cubic splines with five knots (0.58, 3.82, 8.99, 14.98
Oncology January 29,2024
Night work may increase the risk of aggressive prostate cancer in offshore petroleum workers

Night work may increase the risk of aggressive prostate cancer in offshore petroleum workers

by University of Oslo, Faculty of MedicineExposure-risk curve for a non-linear model of rollover shift work exposure, generated using restricted cubic splines with five knots (0.58, 3.82, 8.99, 14.98
Oncology January 29,2024
Research reveals cancer-killing benefits of popular obesity treatment

Research reveals cancer-killing benefits of popular obesity treatment

by Maynooth UniversityCredit: CC0 Public DomainMaynooth University's Kathleen Londsdale Institute for Human Health Research has just published research into the benefits of the popular obesity tre
Oncology January 29,2024
Research reveals cancer-killing benefits of popular obesity treatment

Research reveals cancer-killing benefits of popular obesity treatment

by Maynooth UniversityCredit: CC0 Public DomainMaynooth University's Kathleen Londsdale Institute for Human Health Research has just published research into the benefits of the popular obesity tre
Oncology January 29,2024
Early trial results show benefits of FGFR inhibitors and PARP/ATR inhibitor combinations in multiple tumor types

Early trial results show benefits of FGFR inhibitors and PARP/ATR inhibitor combinations in multiple tumor types

byUniversity of Texas M. D. Anderson Cancer CenterCredit: Pixabay/CC0 Public DomainResearchers from The University of Texas MD Anderson Cancer Center presented promising findings from multiple c
Oncology January 29,2024
Early trial results show benefits of FGFR inhibitors and PARP/ATR inhibitor combinations in multiple tumor types

Early trial results show benefits of FGFR inhibitors and PARP/ATR inhibitor combinations in multiple tumor types

byUniversity of Texas M. D. Anderson Cancer CenterCredit: Pixabay/CC0 Public DomainResearchers from The University of Texas MD Anderson Cancer Center presented promising findings from multiple c
Oncology January 29,2024
Study shows benefit of universal genetic testing after breast cancer diagnosis

Study shows benefit of universal genetic testing after breast cancer diagnosis

byWalter and Eliza Hall Institute of Medical ResearchClassification of 31 participants found to carry pathogenic gene variants, by gene, estimated risk of having a pathogenic gene variant,* and
Oncology January 29,2024
Study shows benefit of universal genetic testing after breast cancer diagnosis

Study shows benefit of universal genetic testing after breast cancer diagnosis

byWalter and Eliza Hall Institute of Medical ResearchClassification of 31 participants found to carry pathogenic gene variants, by gene, estimated risk of having a pathogenic gene variant,* and
Oncology January 29,2024
Researchers identify a promising new drug target for rare liver cancer

Researchers identify a promising new drug target for rare liver cancer

by Rockefeller UniversityCredit: Pixabay/CC0 Public DomainAs a rare and lethal liver cancer that disproportionately harms young adults, fibrolamellar carcinoma is nearly incurable. Surgery can re
Oncology January 29,2024
Researchers identify a promising new drug target for rare liver cancer

Researchers identify a promising new drug target for rare liver cancer

by Rockefeller UniversityCredit: Pixabay/CC0 Public DomainAs a rare and lethal liver cancer that disproportionately harms young adults, fibrolamellar carcinoma is nearly incurable. Surgery can re
Oncology January 29,2024
COVID reforms in cancer care and research could have long-term benefits

COVID reforms in cancer care and research could have long-term benefits

by King's College LondonCredit: Unsplash/CC0 Public DomainA new review led by Professor James Spicer considers the reforms in cancer care and research made due to the pandemic, arguing that s
Oncology January 29,2024
COVID reforms in cancer care and research could have long-term benefits

COVID reforms in cancer care and research could have long-term benefits

by King's College LondonCredit: Unsplash/CC0 Public DomainA new review led by Professor James Spicer considers the reforms in cancer care and research made due to the pandemic, arguing that s
Oncology January 29,2024
Researchers identify the standard for gallbladder cancer surgery

Researchers identify the standard for gallbladder cancer surgery

by Boston University School of MedicineCredit:Annals of Surgical Oncology(2023). DOI: 10.1245/s10434-023-13531-2The quality of surgery can drastically influence both short- and long-t
Oncology January 29,2024
Researchers identify the standard for gallbladder cancer surgery

Researchers identify the standard for gallbladder cancer surgery

by Boston University School of MedicineCredit:Annals of Surgical Oncology(2023). DOI: 10.1245/s10434-023-13531-2The quality of surgery can drastically influence both short- and long-t
Oncology January 29,2024
Fatty liver is increasingly the cause of liver cell cancer

Fatty liver is increasingly the cause of liver cell cancer

by Stefan Zorn, Medizinische Hochschule HannoverCredit: Pixabay/CC0 Public DomainHepatocellular carcinoma (HCC) is one of the most common cancers worldwide. In Germany, there are currently around 9,00
Oncology January 29,2024
Fatty liver is increasingly the cause of liver cell cancer

Fatty liver is increasingly the cause of liver cell cancer

by Stefan Zorn, Medizinische Hochschule HannoverCredit: Pixabay/CC0 Public DomainHepatocellular carcinoma (HCC) is one of the most common cancers worldwide. In Germany, there are currently around 9,00
Oncology January 29,2024
Treatment found to reduce progression of rare blood cancer by 74%

Treatment found to reduce progression of rare blood cancer by 74%

Credit: Wikimedia CommonsA treatment that involves genetically modifying the body's own immune cells has been found to cut the risk of disease progression by 74 percent in people with a rare type
Oncology January 29,2024
Treatment found to reduce progression of rare blood cancer by 74%

Treatment found to reduce progression of rare blood cancer by 74%

Credit: Wikimedia CommonsA treatment that involves genetically modifying the body's own immune cells has been found to cut the risk of disease progression by 74 percent in people with a rare type
Oncology January 29,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com